Equities

Immunitybio Inc

Immunitybio Inc

Actions
  • Price (EUR)4.62
  • Today's Change-0.094 / -2.00%
  • Shares traded0.00
  • 1 Year change+41.60%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments266107317
Total Receivables, Net3.171.891.33
Total Inventory------
Prepaid expenses202616
Other current assets, total4.135.15--
Total current assets294141334
Property, plant & equipment, net183190119
Goodwill, net------
Intangibles, net17201.42
Long term investments0.890.840.82
Note receivable - long term6.886.636.38
Other long term assets2.824.736.78
Total assets504362469
LIABILITIES
Accounts payable9.202111
Accrued expenses464354
Notes payable/short-term debt0432299
Current portion long-term debt/capital leases1.481.42--
Other current liabilities, total1.143.473.94
Total current liabilities58501369
Total long term debt837241306
Total debt838675606
Deferred income tax----0.16
Minority interest1.05(2.49)(1.74)
Other liabilities, total1957037
Total liabilities1,091810711
SHAREHOLDERS EQUITY
Common stock0.070.040.04
Additional paid-in capital2,3751,9311,720
Retained earnings (accumulated deficit)(2962)(2378)(1962)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.010.180.00
Total equity(587)(447)(242)
Total liabilities & shareholders' equity504362469
Total common shares outstanding671422398
Treasury shares - common primary issue0.160.160.16
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.